About 3DHEALS Company Directory:

3DHEALS updates this collection of public and private companies, government and non-government institutions, and any relevant research organizations in healthcare 3D printing, bioprinting, AR/VR, 3D technologies, on a weekly basis. Access to this directory is free to 3DHEALS Premium and Enterprise members. 

THIS CONTENT IS FOR PREMIUM AND ENTERPRISE MEMBERS ONLY.

Register

Add your company to 3DHEALS Directory:

(Please click the same above buttons for significant updates of your organizational information. Map is updated monthly.)

Organization Name
Categories
Headquater location
Description

Mimix Bio

MimiX develops and commercializes a proprietary technology to foster scientific discoveries and clinical translation.

Headquarters Rue de la Pierre-à-Mazel 39 Case postale Microcity Neuchâtel 2000
Categories: Bioprinting /Biofabrication, Pitch3D
Website: www.mimixbio.com
CEO: Marc Thurner
Links:

Details

Technology:

MimiX biotherapeutics’ novel biofabrication technology exploits Sound Induced Morphogenesis (SIM) to create well-defined biological architectures.

Controlled remotely by acoustic waves, SIM allows to pattern of biological material such as cells, organoids, or tissue fragments into three-dimensional constructs that develop into in vitro engineered tissues, for example, microvascular networks.

The SIM technology represents a versatile and time-efficient strategy to create organized cell assemblies at defined spatial resolution and physiologically relevant cell density. The uniqueness of our proprietary technology will allow for clinical translation and push the frontiers of biofabrication both in fundamental and applied research.

CymatiX™:
THE FIRST ACOUSTIC BIOPRINTER. Create biological architectures with sound

Sound Induced Morphogenesis (SIM) is a gentle, fast, and easy method to generate multi-cellular, spatially orchestrated tissue constructs using sound waves.

This versatile method addresses necessities in the broad field of life sciences, finding application in tissue engineering, regenerative medicine, or pharmaceutical research for drug discovery.

With SIM, mimiX biotherapeutics offers the research community a novel R&D platform to complement and advance the existing biofabrication methodologies. SIM provides prospects to overcome some major limitations of conventional methods towards the creation of physiologically relevant in vitro models and engineered tissue constructs.

Application:

3D Bioprinted Skin at the point of care